Q2 2017 EPS Estimates for Vanda Pharmaceuticals Inc. Lowered by Analyst (VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Oppenheimer Holdings dropped their Q2 2017 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a note issued to investors on Thursday. Oppenheimer Holdings analyst D. Archila now expects that the biopharmaceutical company will post earnings per share of ($0.27) for the quarter, down from their prior forecast of ($0.25). Oppenheimer Holdings currently has a “Outperform” rating and a $21.00 target price on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ FY2017 earnings at ($0.77) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.04. The business had revenue of $37.42 million for the quarter, compared to the consensus estimate of $38.35 million. Vanda Pharmaceuticals had a negative return on equity of 10.42% and a negative net margin of 8.85%. TRADEMARK VIOLATION WARNING: This news story was originally posted by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thestockobserver.com/2017/07/18/q2-2017-eps-estimates-for-vanda-pharmaceuticals-inc-lowered-by-analyst-vnda.html.

A number of other research analysts also recently commented on the stock. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. TheStreet raised shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Friday, May 12th. CIBC reissued an “outperform” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. Jefferies Group LLC reissued a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. Finally, HC Wainwright started coverage on shares of Vanda Pharmaceuticals in a research report on Friday, May 26th. They set a “buy” rating and a $18.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $21.22.

Vanda Pharmaceuticals (NASDAQ VNDA) opened at 16.40 on Monday. The stock has a 50 day moving average of $14.44 and a 200 day moving average of $14.49. Vanda Pharmaceuticals has a 52 week low of $10.81 and a 52 week high of $18.00. The company’s market cap is $730.65 million.

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Vanda Pharmaceuticals by 26.4% in the first quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after buying an additional 521,669 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in Vanda Pharmaceuticals by 1,544.3% in the first quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock worth $34,783,000 after buying an additional 2,333,400 shares in the last quarter. State Street Corp boosted its stake in Vanda Pharmaceuticals by 27.2% in the fourth quarter. State Street Corp now owns 1,751,605 shares of the biopharmaceutical company’s stock worth $27,935,000 after buying an additional 374,095 shares in the last quarter. FMR LLC boosted its stake in Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after buying an additional 604,900 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its stake in Vanda Pharmaceuticals by 6.8% in the fourth quarter. Macquarie Group Ltd. now owns 1,372,640 shares of the biopharmaceutical company’s stock worth $21,894,000 after buying an additional 86,891 shares in the last quarter. Institutional investors and hedge funds own 92.51% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply